

CLOSED CUOG TRIALS

11:40 a.m. CUOG P-01b (NHT Taxotere) M Gleave
 11:50 a.m. Taxotere + high dose Calcitriol K Chi

12 NOON **LUNCH**

TRIALS UNDER DEVELOPMENT

1:00 p.m. Antisense bcl-2 + Taxotere in HRPC K Chi
 1:05 p.m. Role of Delayed Treatment for Early Stage RCCa M Jewett
 1:10 p.m. NHT+ Taxotere prior to XRT M McKenzie
 1:15 p.m. NHT + Taxotere prior to RP K Chi/ M Gleave
 1:20 p.m. START: Surveillance Vs intervention early CaP R Choo
 1:25 p.m. Conventional vs hypofraction IMRT C. Catton

REPORT FROM DOGS

1:30 p.m. Advanced Prostate Cancer K Chi
 1:40 p.m. Localized Prostate Cancer L Klotz
 1:50 p.m. Superficial Bladder L Lacombe
 2:00 p.m. Advanced Bladder E Winquist
 2:10 p.m. Kidney S Tanguay
 2:20 p.m. Testes P Warde

2:30 p.m. **Coffee Break**

OTHER TRIALS UNDER CONSIDERATION

2:45 p.m. EORTC Intermediate Risk Testes Trial Update E Winquist / P Warde

CTSU TRIALS

2:50 p.m. **CTSU Presentation**

3:00 p.m. **Endorsed by NCIC CTG**

REC.1/CALGB 90206 A Phase III trial of interferon alpha (IFNA) or IFNA plus bevacizumab in advanced renal carcinoma
 Target accrual 700
 Current accrual 31

3:05 p.m. **Available for endorsement: Active protocols**

RTOG P-0014: Phase III randomized study of patients with high-risk, hormone naïve prostate cancer: Androgen blockade with 4 cycles of immediate chemotherapy versus androgen blockade with delayed chemotherapy
 Target accrual 1050
 Current accrual 10

3:10 p.m. **Protocols in development**

CALGB 90202/CTSU 90202
 A randomized double blind, placebo controlled phase III study of early versus standard Zoledronic Acid to prevent skeletal related events in men with prostate cancer metastatic to bone

3:15 p.m. **Studies submitted to CTSU**

Randomized phase III study of estramustine and docetaxel versus estramustine, docetaxel and bevacizumab in patients with hormone refractory prostate cancer

3:20: p.m. **CUOG AGM**
 Other Business
 Fellowship Opportunities: NCIC CTG/ CUOG

3:30 p.m. Meeting Adjourned